Iterum Therapeutics plc (NASDAQ:ITRM – Get Free Report) Director Michael W. Dunne acquired 20,000 shares of the company’s stock in a transaction dated Wednesday, November 22nd. The shares were bought at an average cost of $2.03 per share, with a total value of $40,600.00. Following the completion of the acquisition, the director now directly owns […]
Iterum Therapeutics plc (NASDAQ:ITRM – Get Free Report) Director Michael W. Dunne purchased 20,000 shares of the stock in a transaction on Wednesday, November 22nd. The stock was acquired at an average price of $2.03 per share, for a total transaction of $40,600.00. Following the completion of the purchase, the director now directly owns 78,754 […]
Iterum Therapeutics plc (NASDAQ:ITRM – Get Free Report) shares dropped 3.4% during mid-day trading on Monday . The stock traded as low as $0.75 and last traded at $0.75. Approximately 17,282 shares were traded during trading, a decline of 71% from the average daily volume of 60,503 shares. The stock had previously closed at $0.78. […]
Iterum Therapeutics plc (NASDAQ:ITRM – Get Free Report) was the recipient of a large growth in short interest during the month of August. As of August 15th, there was short interest totalling 85,700 shares, a growth of 72.8% from the July 31st total of 49,600 shares. Currently, 0.7% of the company’s shares are short sold. […]
Iterum Therapeutics (NASDAQ:ITRM – Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Friday, August 11th. Analysts expect the company to announce earnings of ($0.80) per share for the quarter. Iterum Therapeutics (NASDAQ:ITRM – Get Free Report) last released its quarterly earnings data on Friday, May 12th. The […]